Synthomer Share Discussion Threads

[tricky1992000] 13/12/2019 16:08

Sold out today..... BP looks interesting.

[philanderer] 12/12/2019 10:38

upgrade..

12th dec Morgan Stanley 'neutral' .... tp 300p

[philanderer] 31/10/2019 09:37

++ DEUTSCHE BANK CUTS SYNTHOMER PRICE TARGET TO 340 (375) PENCE - 'BUY' ++

[philanderer] 28/10/2019 09:51

28th oct Peel Hunt 'buy' tp 375p cut from 435p

updated:

28th oct Berenberg buy tp 345p
28th oct Deutsche buy tp 375p
28th oct Peel Hunt buy tp 375p
25th oct Canaccord buy tp 550p


25th oct ++++ Q3 update ++++

[scooper72] 25/10/2019 12:34

My SIPP was already in the red on these but had just bought some for my ISA and they seemed to be doing ok but now those are minus seven percent. Will probably keep both holdings long term as it looks like a good business going forward over the next 10 years and at least there is the dividend which seems well covered and which has been growing over the years.

[philanderer] 25/10/2019 12:29

Plenty of broker comment here..



Canaccord retains 'buy' tp 525p ..... reduced from 550p

[philanderer] 25/10/2019 12:15

'Synthomer warns on profits as macro uncertainties weigh on chemicals industry'

[philanderer] 25/10/2019 09:45

Market report:

In the FTSE 250, Synthomer slumped 12% as it said growing weakness in the global economy is creating a "more challenging" backdrop for the chemicals market.

In the Performance Elastomers unit, there has been continued weakness in the third quarter of 2019 in Europe, and Synthomer has now started a review, saying it will update on "asset re-purposing and cost base" in March next year.

The company expects slower trading to continue for the rest of 2019 and into 2020. If current weakness continues as is, Synthomer said, 2019 underlying pretax profit will be 10% below 2018 and 10% off market consensus of GBP135.3 million.

Alliance News

[philanderer] 25/10/2019 09:34

Should be chart support at 230p.

[philanderer] 25/10/2019 09:31

Peel Hunt reiterating their 'buy' but I reckon their previous 435p tp may be revised down in the next few days.

Not sure what Canaccord were thinking a couple of weeks ago with their 550p target.

[philanderer] 25/10/2019 09:10

Not a surprise really. ZTF gave a similar profit warning a few weeks ago.

Be back up to 300p in two years easily.

[philanderer] 04/10/2019 00:24

Zotefoam’s share price has fallen a whopping 36% in early morning trade to 340p as the specialist chemicals firm warned that sales of polyolefin foam, its biggest-selling product, are likely to be £6m below market forecasts

[philanderer] 03/10/2019 12:10

Looks like the warning on polyolefin from ZTF ... common to SYNT.

[philanderer] 03/10/2019 12:01

Canaccord this morning saying 'buy'... tp 550p

[philanderer] 03/10/2019 11:59

buywell, good spot. I think you're bang on , thanks.

[buywell3] 03/10/2019 08:58

Has Zotefoams news hurt this ?

Mmmm

Coming Global Downturn looks the problem

[philanderer] 03/10/2019 08:41

Oh dear...that's dropped way more than just going xd

[philanderer] 02/10/2019 14:39

xd tomorrow morning for ther 4p dividend

[philanderer] 16/9/2019 20:31

Peel Hunt reiterates BUY ,tp 435p cut from 450p

[robow] 15/9/2019 09:21

GREAT IDEAS
10 | SHARES | 12 September 2019

Chemicals firm Synthomer (SYNT) looks very tempting at the current price following a big sell-off over the past year. The firm’s share price dropped from around 530p a year ago to 280p last month and saw the stock trade on nearly its lowest rating in a decade, while its level of debt compared to how much it’s earning is expected to double. But with the business on the cusp of global expansion as it aims to keep up with soaring demand for its products, investors with a long-term view may want to take advantage of the firm’s cheap valuation. The chemicals sector has historically been a good place to invest with significant share price gains over the past decade and occasionally generous dividends. But chemicals companies have been caught up by concerns over a global economic slowdown in the past year, and some in the market think this may feed into weaker demand for chemicals products. Synthomer has tried to expand significantly to keep up with demand for its speciality products, sought after due to many factors such as urbanisation, ageing demographics and stricter legislation. The firm supplies aqueous polymers to companies, which
The company should benefit from capacity expansion and a deal to boost its position in the US and Europe
The outlook is looking brighter for Synthomer
Synthomer is also forecast by analysts at Canaccord and Numis to have a much stronger second half of this year as market conditions are set to improve. That combined with its completed upgrades to facilities in Germany and Malaysia means the firm will have greater capacity to meet demand for its products. Its net debt-to-earnings ratio is expected to increase next year to between 2.2 and 3-times as the Omnova deal is completed. But Synthomer has a clear plan to get this down below 2-times by the end of 2021. Its management team has a disciplined approach to M&A, with a ‘conservative capital’ policy meaning it’s unlikely to ever be reckless in the pursuit of growth.
help create new products and boost the performance of existing ones, such as footwear insoles, condoms, packaging tapes, carpets and waterproofing products. While strong on the consumer side, investors had questioned Synthomer’s growth prospects given its lack of real penetration into the industrial market. But the proposed deal to acquire Omnova Solutions, an American speciality chemicals business operating in sectors like construction and oil and gas, could make the market reappraise Synthomer. As well as the US, Omnova has manufacturing and technical facilities in Europe, Thailand and China. Analysts at UBS believe the acquisition will help Synthomer sell more products in the US, and help it expand its facilities in Europe.

SYNT is also forecast by
analysts at Canaccord and Numis to have a much stronger second half of this year as market conditions are set to improve. That combined with its completed upgrades to facilities in Germany and Malaysia means the firm will have greater capacity to meet demand for its products. Its net debt-to-earnings ratio is expected to increase next year to between 2.2 and 3-times as the Omnova deal is completed. But Synthomer has a clear plan to get this down below 2-times by the end of 2021. Its management team has a disciplined approach to M&A, with a ‘conservative capital’ policy meaning it’s unlikely to ever be reckless in the pursuit of growth.
help create new products

[circles of stone] 14/9/2019 21:16

Can you post the article, please

[philanderer] 13/9/2019 10:10

13th sept Berenberg buy tp 360p

reiterates.

[philanderer] 12/9/2019 11:30

Thanks robow.